Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899016 | 0.90 | NR4A2 (0.50) | NR4A2MAPTTDP1MEN1KMT2A | |
| SCHEMBL1010947 | 0.88 | DHODH (0.48) | NR4A2KMT2A | |
| SCHEMBL8510685 | 0.88 | PLA2G2A (0.51) | NR4A2MAPTPLA2G2A | |
| SCHEMBL9899615 | 0.86 | PLA2G2A (0.49) | NR4A2MAPTTDP1PLA2G2A | |
| SCHEMBL6383895 | 0.83 | BACE1 (0.51) | NR4A2MAPTTDP1PLA2G2AFPR1 | |
| SCHEMBL9899201 | 0.83 | NR4A2 (0.46) | NR4A2MAPTTDP1MEN1KMT2A | |
| SCHEMBL1011786 | 0.82 | DHODH (0.45) | NR4A2MAPTPOLBKMT2A | |
| SCHEMBL1009498 | 0.80 | TSHR (0.48) | NR4A2MAPTTDP1MEN1KMT2A | |
| SCHEMBL1332988 | 0.79 | KDM4E (0.46) | MAPTPOLBKMT2A | |
| SCHEMBL31435276 | 0.79 | KDM4E (0.46) | MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651914-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8920928-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2651914-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082999-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | CRY2, CRY1, IPO4 | NR4A2 337/4885MAPT 562/4885TDP1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.